Imugene (ASX: IMU) welcomes Dr Weitzman as interim chief medical officer

July 18, 2023 07:04 PM AEST | By Team Kalkine Media

Google News:

Imugene (ASX: IMU) welcomes Dr Weitzman as interim chief medical officer — Image source: Imugene PPT

Recent News

Australia and New Zealand Currencies Face Volatility Ahead of Fed Deci...

Middle East Tensions Weigh on Australia Equity Market Performance

Labor and the Australia Equity Market: Is the Political Shift Really C...

Australia Equity Market Sees Growth in Cryptocurrency Sector by 2025

Highlights

Imugene has appointed Dr Ron Weitzman as its interim CMO.

Dr Weitzman has an experience of over 20 years in the biopharmaceutical space.

Dr Weitzman has extensive record in clinical development plan development and execution.

Australian immuno-oncology company Imugene Limited (ASX: IMU) has roped in Dr Ron Weitzman as its interim chief medical officer.

About Dr Weitzman

Dr Weitzman has over 20 years of global experience in the biopharmaceutical space. He carries expertise in the therapeutic areas of hematologic malignancies and solid tumour. He has a considerable record in directing Phase I-III clinical trials, developing and executing clinical development plans, and formulating regulatory submissions in the US and the EU.

Past experience of Dr Weitzman

Prior to joining Imugene, Dr Weitzman held leadership roles at biopharmaceutical companies such as Novartis, Genentech, Exelixis and Tango Therapeutics.

Here is the detail of the most recent roles held by him –

Data source: company update

Dr Weitzman graduated from the University of Western Ontario, Canada.

Data source: company update

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.